PD-L1和PD-1在胸腺癌中的表达情况和临床意义
Expression and Clinical Significance of PD-L1 and PD-1 in Thymic Carcinoma
DOI: 10.12677/ACM.2023.133531, PDF,   
作者: 王 雪：延安大学附属医院病理科，陕西 延安；空军军医大学第二附属医院病理科，陕西 西安；杜 雄*：延安大学附属医院病理科，陕西 延安
关键词: 胸腺癌；程序性死亡配体1；程序性死亡受体1；免疫治疗；Thymic Carcinoma； PD-L1； PD-1； Immunotherapy
摘要: 近几年，应用免疫检查点抑制剂阻断PD-1/PD-L1信号通路的免疫治疗在多种恶性肿瘤中表现出显著的临床获益。胸腺癌作为一种罕见的恶性肿瘤，预后较差，治疗方式有限。目前已有证据表明PD-L1在胸腺癌中高表达且其表达情况与预后相关。本文就PD-L1和PD-1在胸腺癌中的临床研究进展作一综述。
Abstract: In recent years, immunotherapy with the application of immune checkpoint inhibitors to block the PD-1/PD-L1 signaling pathway has shown significant clinical benefit in a variety of malignancies. Thymic carcinoma, a rare malignancy, has a poor prognosis and limited therapeutic options. It has been proved that PD-L1 is highly expressed in thymic carcinoma and its expression level is signifi-cantly correlated with the prognosis of thymic carcinoma. This article reviews the clinical research progress of PD-L1 and PD-1 in thymic carcinoma.
文章引用：王雪, 杜雄. PD-L1和PD-1在胸腺癌中的表达情况和临床意义[J]. 临床医学进展, 2023, 13(3): 3702-3708. https://doi.org/10.12677/ACM.2023.133531

参考文献

[1] Yang, X., et al. (2017) The Optimal First-Line Treatment for Advanced Thymic Carcinomas. Journal of Thoracic On-cology, 12, S2061. [Google Scholar] [CrossRef] 
[2] Eng, T.Y., et al. (2004) Thymic Carcinoma: State of the Art Review. International Journal of Radiation Oncology Biology Physics, 59, 654-664. [Google Scholar] [CrossRef] [PubMed]
[3] Kurup, A. and Loehrer, P.J. (2004) Thymoma and Thymic Car-cinoma: Therapeutic Approaches. Clinical Lung Cancer, 6, 28-32. [Google Scholar] [CrossRef] 
[4] Litvak, A.M., et al. (2014) Clinical Characteristics and Outcomes for Patients with Thymic Carcinoma: Evaluation of Masaoka Staging. Journal of Thoracic Oncology, 9, 1810-1815. [Google Scholar] [CrossRef] 
[5] Thomas, A., et al. (2015) Sunitinib in Patients with Chemo-therapy-Refractory Thymoma and Thymic Carcinoma: An Open-Label Phase 2 Trial. The Lancet Oncology, 16, 177-186. [Google Scholar] [CrossRef] 
[6] Yokoyama, S., et al. (2016) Prognostic Value of Pro-grammed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma. Clinical Cancer Research, 22, 4727-4734. [Google Scholar] [CrossRef] 
[7] Girard, N. (2014) Chemotherapy and Targeted Agents for Thymic Malignancies. Expert Review of Anticancer Therapy, 12, 685-695. [Google Scholar] [CrossRef] [PubMed]
[8] Giaccone, G., et al. (2018) Pembrolizumab in Patients with Thymic Carci-noma: A Single-Arm, Single-Centre, Phase 2 Study. The Lancet Oncology, 19, 347-355. [Google Scholar] [CrossRef] 
[9] Cho, J., et al. (2018) Pembrolizumab for Patients with Re-fractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. Journal of Clinical Oncology, 37, 2162-2170.
[10] 王凯瑞, 等. 胸腺上皮肿瘤中程序性死亡蛋白1及其配体的临床研究进展[J]. 现代肿瘤医学, 2020, 28(9): 1580-1582.
[11] Ferris, R.L., et al. (2016) Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 375, 1856-1867. [Google Scholar] [CrossRef] 
[12] Postow, M.A., et al. (2015) Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine, 372, 2006-2017. [Google Scholar] [CrossRef] 
[13] Reck, M., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 375, 1823-1833. [Google Scholar] [CrossRef] 
[14] Motzer, R.J., et al. (2015) Nivolumab versus Everolimus in Ad-vanced Renal-Cell Carcinoma. New England Journal of Medicine, 373, 1803-1813. [Google Scholar] [CrossRef] 
[15] Takashi Kojima, M., et al. (2020) Randomized Phase III KEYNOTE-181 Study of Pembrolizumab versus Chemotherapy in Advanced Esophageal Cancer. Journal of Clinical Oncology, 38, 4138-4148. [Google Scholar] [CrossRef] 
[16] Keir, M.E., et al. (2008) PD-1 and Its Ligands in Tolerance and Im-munity. Annual Review of Immunology, 26, 677-704. [Google Scholar] [CrossRef] [PubMed]
[17] Sharpe, A.H., et al. (2007) The Function of Pro-grammed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection. Nature Immunology, 8, 239-245. [Google Scholar] [CrossRef] [PubMed]
[18] Okazaki, T. and Honjo, T. (2007) PD-1 and PD-1 Ligands: From Discovery to Clinical Application. International Immunology, 19, 813-824. [Google Scholar] [CrossRef] [PubMed]
[19] Nurieva, R.I., Liu, X. and Dong, C. (2009) Yin-Yang of Costimulation: Crucial Controls of Immune Tolerance and Function. Immunological Reviews, 229, 88-100. [Google Scholar] [CrossRef] 
[20] Francisco, L.M., Sage, P.T. and Sharpe, A.H. (2010) The PD-1 Pathway in Tolerance and Autoimmunity. Immunological Reviews, 236, 219-242. [Google Scholar] [CrossRef] 
[21] Katsuya, Y., et al. (2015) Immunohistochemical Status of PD-L1 in Thymoma and Thymic Carcinoma. Lung Cancer, 88, 154-159. [Google Scholar] [CrossRef] [PubMed]
[22] Giaccone, G. and Kim, C. (2021) Durable Response in Patients with Thymic Carcinoma Treated with Pembrolizumab after Prolonged Follow-Up. Journal of Thoracic Oncology, 16, 483-485. [Google Scholar] [CrossRef] [PubMed]
[23] Katsuya, Y., et al. (2019) Single-Arm, Multicentre, Phase II Trial of Nivolumab for Unresectable or Recurrent Thymic Carcinoma: PRIMER Study. European Journal of Cancer, 113, 78-86. [Google Scholar] [CrossRef] [PubMed]
[24] Sakane, T., et al. (2018) A Comparative Study of PD-L1 Immunohistochemical Assays with Four Reliable Antibodies in Thymic Carcinoma. Oncotarget, 9, 6993-7009. [Google Scholar] [CrossRef] [PubMed]
[25] Katsuya, Y., et al. (2016) Expression of Programmed Death 1 (PD-1) and Its Ligand (PD-L1) in Thymic Epithelial Tumors: Impact on Treatment Efficacy and Alteration in Expression after Chemotherapy. Lung Cancer, 99, 4-10. [Google Scholar] [CrossRef] [PubMed]
[26] Weissferdt, A., et al. (2017) Expression of PD-1 and PD-L1 in Thymic Epithelial Neoplasms. Modern Pathology, 30, 826-833. [Google Scholar] [CrossRef] [PubMed]
[27] Chen, Y., et al. (2018) Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors. BioMed Research International, 2018, Article ID: 5830547. [Google Scholar] [CrossRef] [PubMed]
[28] Duan, J., et al. (2018) Impact of PD-L1, Transforming Growth Fac-tor-Beta Expression and Tumor-Infiltrating CD8(+) T Cells on Clinical Outcome of Patients with Advanced Thymic Epi-thelial Tumors. Thoracic Cancer, 9, 1341-1353. [Google Scholar] [CrossRef] [PubMed]
[29] Funaki, S., et al. (2019) The Prognostic Impact of Programmed Cell Death 1 and Its Ligand and the Correlation with Epithelial-Mesenchymal Transition in Thymic Carcinoma. Cancer Medi-cine, 8, 216-226. [Google Scholar] [CrossRef] [PubMed]
[30] Song, J.S., et al. (2019) Clinicopathologic Significance and Immunoge-nomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epi-thelial Tumors. Frontiers in Oncology, 9, 1055. [Google Scholar] [CrossRef] [PubMed]
[31] Rouquette, I., et al. (2019) Immune Biomarkers in Thymic Epithelial Tumors: Expression Patterns, Prognostic Value and Comparison of Diagnostic Tests for PD-L1. Biomarker Research, 7, Article No. 28. [Google Scholar] [CrossRef] [PubMed]
[32] 杨映红, 吴龙, 冯昌银, 黄建平. 胸腺鳞状细胞癌41例临床病理分析及PD-L1表达的意义[J]. 临床与实验病理学杂志, 2021, 37(10): 1227-1230.
[33] Kashima, J., et al. (2022) CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets. Frontiers in Oncology, 11, Article ID: 808396. [Google Scholar] [CrossRef] [PubMed]
[34] Isshiki, T., et al. (2018) Suc-cessful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression. Case Reports in Oncology, 11, 688-692. [Google Scholar] [CrossRef] [PubMed]
[35] Yang, P., et al. (2018) Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma. Journal of Thoracic Oncology, 13, e36-e39. [Google Scholar] [CrossRef] [PubMed]
[36] Rajan, A., et al. (2019) Efficacy and Tolerability of An-ti-Programmed Death-Ligand 1 (PD-L1) Antibody (Avelumab) Treatment in Advanced Thymoma. Journal for Immu-noTherapy of Cancer, 7, 269. [Google Scholar] [CrossRef] [PubMed]
[37] Cafaro, A., et al. (2020) Pembrolizumab in a Patient with Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review. Frontiers in Oncology, 10, 1478. [Google Scholar] [CrossRef] [PubMed]
[38] Thomas, Q.D., et al. (2022) Pembrolizumab plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report. Frontiers in Oncology, 11, Article ID: 814544. [Google Scholar] [CrossRef] [PubMed]
[39] Rajan, A., et al. (2021) The Role of Immunotherapy for Manage-ment of Advanced Thymic Epithelial Tumors: A Narrative Review. Mediastinum, 5, 23. [Google Scholar] [CrossRef] [PubMed]
[40] Rajan, A. (2021) Immunotherapy for Thymic Cancers: A Convoluted Path toward a Cherished Goal. Journal of Thoracic Oncology, 16, 352-354. [Google Scholar] [CrossRef] [PubMed]
[41] Brahmer, J., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373, 123-135. [Google Scholar] [CrossRef] 
[42] Borghaei, H., et al. (2015) Nivolumab versus Docetaxel in Ad-vanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373, 1627-1639. [Google Scholar] [CrossRef] 

为你推荐